Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer

Preliminary Data Suggestion Possibility of Localized Gene Silencing Utilizing Clinically Used Transcatheter Arterial Chemoembolization Procedure for siRNA Deliver

Aug 31, 2015, 08:30 ET from Regen BioPharma Inc.

SAN DIEGO, Aug. 31, 2015 /PRNewswire/ -- Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system.  The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.  By utilizing a local delivery system, potential toxicities are reduced and a higher concentration of the therapeutic product reaches the tumor.

"Historically our approach at Regen BioPharma has always been to aim for as little systemic delivery as possible.  In our dCellVax product (FDA IND # 16200) the gene silencing is performed on immune cells before administration to the body.  In our current product, the gene silencing agent is administered using a "depot" formulation that conventionally is utilized for local delivery of chemotherapy as a palliative approach to unresectable liver cancer patients," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. "In contrast to chemotherapy, which does not target cancer stem cells, there is evidence suggesting that gene silencing of BORIS does kill cancer stem cells[1].  By killing cancer stem cells we believe that our new approach in development will lead to improved efficacy of the clinically used Transcatheter Arterial Chemoembolization procedure."

Liver cancer is the 6th most common cancer world-wide, with 786,000 new cases every year. Risk factors for liver cancer include hepatitis infection, as well as excessive alcohol use[2].

"The company continues to develop intellectual property, with the filing of patent application number 62211605 to cover this novel combination procedure," said David Koos, PhD, Chairman and CEO of Regen BioPharma. "We are now in the process of seeking clinical collaborators with the hope of filing an Investigational New Drug (IND) Application with the FDA on this technology next year."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information
Regen BioPharma Inc. 
David R. Koos, PhD 
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharmainc.com/
david.koos@regenbiopharma.com

[1] http://www.prnewswire.com/news-releases/regen-biopharma-inc-boris-gene-silencing-technology-successfully-utilized-by-independent-researchers-to-kill-breast-cancer-and-colon-cancer-stem-cells-300132125.html

[2] http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics

SOURCE Regen BioPharma Inc.



RELATED LINKS

http://www.regenbiopharmainc.com/